PL2501703T3 - Spiropiperydynowe związki jako antagoniści receptora orl-1 - Google Patents

Spiropiperydynowe związki jako antagoniści receptora orl-1

Info

Publication number
PL2501703T3
PL2501703T3 PL10782482T PL10782482T PL2501703T3 PL 2501703 T3 PL2501703 T3 PL 2501703T3 PL 10782482 T PL10782482 T PL 10782482T PL 10782482 T PL10782482 T PL 10782482T PL 2501703 T3 PL2501703 T3 PL 2501703T3
Authority
PL
Poland
Prior art keywords
orl
receptor antagonists
spiropiperidine compounds
spiropiperidine
compounds
Prior art date
Application number
PL10782482T
Other languages
English (en)
Polish (pl)
Inventor
Collado Ana Belen Benito
Buezo Nuria Diaz
Alma Maria Jimenez-Aguado
Blanco Celia Lafuente
Maria Angeles Martinez-Grau
Concepcion Pedregal-Tercero
Escribano Miguel Angel Toledo
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PL2501703T3 publication Critical patent/PL2501703T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL10782482T 2009-11-16 2010-11-10 Spiropiperydynowe związki jako antagoniści receptora orl-1 PL2501703T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP09382246 2009-11-16
US29862910P 2010-01-27 2010-01-27
PCT/US2010/056180 WO2011060035A1 (en) 2009-11-16 2010-11-10 Spiropiperidine compounds as orl-1 receptor antagonists
EP10782482.3A EP2501703B1 (en) 2009-11-16 2010-11-10 Spiropiperidine compounds as orl-1 receptor antagonists

Publications (1)

Publication Number Publication Date
PL2501703T3 true PL2501703T3 (pl) 2014-02-28

Family

ID=41728051

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10782482T PL2501703T3 (pl) 2009-11-16 2010-11-10 Spiropiperydynowe związki jako antagoniści receptora orl-1

Country Status (34)

Country Link
US (1) US8232289B2 (enExample)
EP (1) EP2501703B1 (enExample)
JP (1) JP5680101B2 (enExample)
KR (1) KR101363830B1 (enExample)
CN (1) CN102612520B (enExample)
AR (1) AR078863A1 (enExample)
AU (1) AU2010319581C1 (enExample)
CA (1) CA2796161C (enExample)
CO (1) CO6541545A2 (enExample)
CR (1) CR20130087A (enExample)
DK (1) DK2501703T3 (enExample)
DO (1) DOP2012000135A (enExample)
EA (1) EA020848B1 (enExample)
EC (1) ECSP12011902A (enExample)
ES (1) ES2435814T3 (enExample)
HN (1) HN2012001011A (enExample)
HR (1) HRP20130967T1 (enExample)
IL (1) IL219370A (enExample)
JO (1) JO2887B1 (enExample)
MA (1) MA33751B1 (enExample)
ME (1) ME01537B (enExample)
MX (1) MX2012005691A (enExample)
MY (1) MY160665A (enExample)
NZ (1) NZ600006A (enExample)
PE (1) PE20121430A1 (enExample)
PH (1) PH12012500969A1 (enExample)
PL (1) PL2501703T3 (enExample)
PT (1) PT2501703E (enExample)
RS (1) RS53018B (enExample)
SI (1) SI2501703T1 (enExample)
TW (1) TWI465453B (enExample)
UA (1) UA107943C2 (enExample)
WO (1) WO2011060035A1 (enExample)
ZA (1) ZA201202967B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011069063A2 (en) * 2009-12-04 2011-06-09 Sunovion Pharmaceuticals, Inc. Multicyclic compounds and methods of use thereof
JP2013540145A (ja) * 2010-10-21 2013-10-31 ウニベルシテート デス ザールランデス コルチゾール依存性疾患の治療用の選択的cyp11b1阻害剤
TWI582096B (zh) * 2011-12-06 2017-05-11 美國禮來大藥廠 用於酒精依賴及濫用處理之4',5'-二氫螺[哌啶-4,7'-噻吩并[2,3-c]哌喃]化合物
TW201416370A (zh) 2012-07-31 2014-05-01 Lilly Co Eli 用於治療焦慮之orl-1受體拮抗劑
US9802899B2 (en) 2012-10-02 2017-10-31 Bayer Cropscience Ag Heterocyclic compounds as pesticides
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
TW201607923A (zh) 2014-07-15 2016-03-01 歌林達有限公司 被取代之氮螺環(4.5)癸烷衍生物
JO3638B1 (ar) 2015-09-09 2020-08-27 Lilly Co Eli مركبات مفيدة في تثبيط ror - جاما- t
HUE070203T2 (hu) 2016-07-29 2025-05-28 Sumitomo Pharma America Inc Vegyületek és készítmények és alkalmazásaik
AU2017301767A1 (en) 2016-07-29 2019-02-14 Pgi Drug Discovery Llc Compounds and compositions and uses thereof
WO2018151861A1 (en) 2017-02-16 2018-08-23 Sunovion Pharamaceuticials Inc. Methods of treating schizophrenia
RS61935B1 (sr) * 2017-03-02 2021-07-30 Lilly Co Eli Jedinjenja korisna za inhibiciju ror-gama-t
SI3589638T1 (sl) 2017-03-02 2021-08-31 Eli Lilly And Company Spojine uporabne pri inhibiciji ROR-GAMMA-T
AU2018312559B2 (en) 2017-08-02 2022-06-02 Pgi Drug Discovery Llc Isochroman compounds and uses thereof
CA3091292A1 (en) 2018-02-16 2019-08-22 Sunovion Pharmaceuticals Inc. Salts, crystal forms, and production methods thereof
IL283592B2 (en) 2018-12-17 2025-08-01 Vertex Pharma Inhibitors of apol1 and methods of using same
KR20210139376A (ko) 2019-03-14 2021-11-22 선오비온 파마슈티컬스 인코포레이티드 이소크로마닐 화합물의 염, 및 이의 결정성 형태, 제조방법, 치료 용도 및 약제학적 조성물
EP4135690A1 (en) 2020-04-14 2023-02-22 Sunovion Pharmaceuticals Inc. (s)-(4,5-dihydro-7h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine for treating neurological and psychiatric disorders
MX2023002269A (es) 2020-08-26 2023-05-16 Vertex Pharma Inhibidores de apol1 y metodos para usar los mismos.
AU2023218994A1 (en) * 2022-02-08 2024-08-22 Vertex Pharmaceuticals Incorporated 2-methyl-4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL96507A0 (en) 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
WO2001039723A2 (en) 1999-12-06 2001-06-07 Euro-Celtique, S.A. Triazospiro compounds having nociceptin receptor affinity
HUP0401333A3 (en) 2001-04-18 2004-11-29 Euro Celtique Sa Spiropyrazole compounds and pharmaceutical compositions containing them
WO2002088089A1 (en) 2001-04-19 2002-11-07 Banyu Pharmaceutical Co., Ltd. Spiropiperidine derivatives, nociceptin receptor antagonists containing the same as the active ingredient and medicinal compositions
US7192964B2 (en) 2001-07-23 2007-03-20 Banyu Pharmaceutical Co., Ltd. 4-oxoimidazolidine-2-spiropiperidine derivatives
WO2003064425A1 (en) * 2002-01-28 2003-08-07 Pfizer Japan Inc. N-substituted spiropiperidine compounds as ligands for orl-1 receptor
JPWO2003095427A1 (ja) 2002-05-10 2005-09-15 大正製薬株式会社 スピロ環化合物
US6995168B2 (en) 2002-05-31 2006-02-07 Euro-Celtique S.A. Triazaspiro compounds useful for treating or preventing pain
NZ538307A (en) 2002-09-09 2008-04-30 Janssen Pharmaceutica Nv Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
WO2005016913A1 (en) * 2003-08-19 2005-02-24 Pfizer Japan, Inc. Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders
DE10360792A1 (de) * 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
US7354925B2 (en) * 2004-03-29 2008-04-08 Pfizer Inc. Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as ORL1-receptor antagonists
DE102004039382A1 (de) * 2004-08-13 2006-02-23 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
EP2020414A1 (en) 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis
US8293758B2 (en) 2008-03-27 2012-10-23 Grunenthal Gmbh Substituted spirocyclic cyclohexane derivatives

Also Published As

Publication number Publication date
AU2010319581B2 (en) 2013-12-19
ECSP12011902A (es) 2012-07-31
SI2501703T1 (sl) 2013-11-29
KR20130026523A (ko) 2013-03-13
DOP2012000135A (es) 2012-08-15
IL219370A (en) 2015-01-29
AU2010319581A1 (en) 2012-06-07
EA201290352A1 (ru) 2012-10-30
UA107943C2 (xx) 2015-03-10
HN2012001011A (es) 2015-08-31
TWI465453B (zh) 2014-12-21
ZA201202967B (en) 2013-09-25
CN102612520A (zh) 2012-07-25
IL219370A0 (en) 2012-06-28
AU2010319581C1 (en) 2014-05-15
JP2013510859A (ja) 2013-03-28
CA2796161A1 (en) 2011-05-19
RS53018B (sr) 2014-04-30
CR20130087A (es) 2013-04-17
US20110118251A1 (en) 2011-05-19
NZ600006A (en) 2014-05-30
JO2887B1 (en) 2015-03-15
US8232289B2 (en) 2012-07-31
TW201127841A (en) 2011-08-16
CN102612520B (zh) 2015-04-08
ME01537B (me) 2014-04-20
JP5680101B2 (ja) 2015-03-04
AR078863A1 (es) 2011-12-07
PH12012500969A1 (en) 2013-01-07
EP2501703B1 (en) 2013-09-18
DK2501703T3 (da) 2013-10-14
MY160665A (en) 2017-03-15
EP2501703A1 (en) 2012-09-26
PE20121430A1 (es) 2012-10-26
CO6541545A2 (es) 2012-10-16
MX2012005691A (es) 2012-06-13
ES2435814T3 (es) 2013-12-23
HK1169988A1 (en) 2013-02-15
EA020848B1 (ru) 2015-02-27
CA2796161C (en) 2015-03-17
PT2501703E (pt) 2013-11-26
WO2011060035A1 (en) 2011-05-19
MA33751B1 (fr) 2012-11-01
HRP20130967T1 (hr) 2013-11-22
KR101363830B1 (ko) 2014-02-14

Similar Documents

Publication Publication Date Title
IL219370A0 (en) Spiropiperidine compounds as orl-1 receptor antagonists
SI2501704T1 (sl) Spojine spiropiperidina kot antagonisti oral-1 receptorja
GB2474748B (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
AP2739A (en) Azaindazole compounds as CCRI receptor antagonists
GB2474120B (en) Compounds as Lysophosphatidic acid receptor antagonists
PT2927224T (pt) Antagonistas de receptores
EP2462128A4 (en) COMPOUNDS AS LYSOPHOSPHATIDE ACID RECEPTOR ANAGONISTS
ZA201203452B (en) Cgrp receptor antagonists
IL200804A0 (en) Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists
IL219594A0 (en) Novel spiropiperidine compounds
IL217526A0 (en) Carbocyclic glyt1 receptor antagonists
ZA201007988B (en) Quinuclidine derivatives as muscarinic m3 receptor antagonists
IL213982A0 (en) Piperidine derivatives as nk3 receptor antagonists
IL214731A0 (en) Uses of nk receptor antagonists
ZA201005341B (en) Methods for inhibiting angiogenesis using egfl8 antagonists
EP2566494A4 (en) CXCR4 RECEPTOR COMPOUNDS
ZA201301561B (en) 5-ht2b receptor antagonists
IL213769A0 (en) Piperidine derivatives as nk3 receptor antagonists
GB0901836D0 (en) EP4 receptor antagonists
GB0900756D0 (en) EP4 Receptor antagonists
GB0900755D0 (en) Ep4 receptor antagonists
GB0900754D0 (en) EP4 Receptor antagonists
GB0922455D0 (en) Ep2 receptor antagonists
ZA200906393B (en) Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists
HK1167860A (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists